CO6351779A2 - Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos - Google Patents

Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos

Info

Publication number
CO6351779A2
CO6351779A2 CO11034471A CO11034471A CO6351779A2 CO 6351779 A2 CO6351779 A2 CO 6351779A2 CO 11034471 A CO11034471 A CO 11034471A CO 11034471 A CO11034471 A CO 11034471A CO 6351779 A2 CO6351779 A2 CO 6351779A2
Authority
CO
Colombia
Prior art keywords
molecula
inhibitors
small
androgen receptor
terminal activation
Prior art date
Application number
CO11034471A
Other languages
English (en)
Inventor
Marianne D Sadar
Nasrin Mawji
Jun Wang
Raymond J Andersen
David E Williams
Mike Leblanc
lu-ping Yan
Original Assignee
British Columbia Cancer Agency
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41706796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351779(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by British Columbia Cancer Agency, Univ British Columbia filed Critical British Columbia Cancer Agency
Publication of CO6351779A2 publication Critical patent/CO6351779A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Abstract

Se proporcionan compuestos que tienen una estructura de Fórmula (A). Se proporcionan usos de dichos compuestos para el tratamiento de varias indicaciones, incluyendo cáncer de próstata, así como métodos de tratamiento que involucran dichos compuestos. También se proporcionan usos de compuestos que tienen una estructura de Fórmula (F) para el tratamiento de varias indicaciones, incluyendo cáncer de próstata, así como métodos de tratamiento que involucran dichos compuestos.
CO11034471A 2008-08-22 2011-03-22 Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos CO6351779A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13627708P 2008-08-22 2008-08-22

Publications (1)

Publication Number Publication Date
CO6351779A2 true CO6351779A2 (es) 2011-12-20

Family

ID=41706796

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11034471A CO6351779A2 (es) 2008-08-22 2011-03-22 Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos

Country Status (14)

Country Link
US (2) US9487479B2 (es)
EP (1) EP2331501B1 (es)
JP (1) JP2012500778A (es)
CN (1) CN102131775B (es)
AU (1) AU2009284668B2 (es)
BR (1) BRPI0917818A2 (es)
CA (1) CA2728103C (es)
CL (1) CL2011000341A1 (es)
CO (1) CO6351779A2 (es)
ES (1) ES2593859T3 (es)
HK (1) HK1153198A1 (es)
MX (1) MX339300B (es)
RU (1) RU2519948C2 (es)
WO (1) WO2010020055A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519948C2 (ru) 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
US9682933B2 (en) * 2014-05-30 2017-06-20 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10799416B2 (en) * 2017-01-11 2020-10-13 Jonathan Taves Self-treating upper neck system for therapeutic mobilization
CN107353239B (zh) 2017-08-11 2019-06-18 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法
CN107468690B (zh) * 2017-08-11 2020-01-31 北京卓凯生物技术有限公司 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
RU2700573C2 (ru) * 2017-10-16 2019-09-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2694259C2 (ru) * 2017-10-16 2019-07-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2696287C2 (ru) * 2017-10-16 2019-08-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты
RU2694373C2 (ru) * 2017-10-16 2019-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кировский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Кировский ГМУ Минздрава России) Способ лечения кастрационно-устойчивого рака простаты

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0317057A (ja) * 1989-06-15 1991-01-25 Fujisawa Pharmaceut Co Ltd 新規５員環複素環化合物
AU4494399A (en) 1998-06-30 2000-01-24 University Of British Columbia, The Inhibitors of androgen-independent activation of androgen receptor
HUP0302358A3 (en) * 2000-05-09 2007-09-28 Adpharma Piperazinedione compounds and use of them for producing pharmaceutical compositions
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
RU2519948C2 (ru) 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
US9682933B2 (en) * 2014-05-30 2017-06-20 British Columbia Cancer Agency Branch Androgen receptor modulators and methods for their use

Also Published As

Publication number Publication date
HK1153198A1 (zh) 2012-03-23
WO2010020055A1 (en) 2010-02-25
RU2011110743A (ru) 2012-09-27
AU2009284668B2 (en) 2015-07-09
BRPI0917818A2 (pt) 2017-02-21
CN102131775A (zh) 2011-07-20
MX2011001890A (es) 2011-06-20
EP2331501A4 (en) 2012-06-06
EP2331501A1 (en) 2011-06-15
CA2728103A1 (en) 2010-02-25
AU2009284668A1 (en) 2010-02-25
US9487479B2 (en) 2016-11-08
CA2728103C (en) 2017-06-27
ES2593859T3 (es) 2016-12-13
CN102131775B (zh) 2015-12-16
JP2012500778A (ja) 2012-01-12
CL2011000341A1 (es) 2011-09-02
MX339300B (es) 2016-05-19
RU2519948C2 (ru) 2014-06-20
EP2331501B1 (en) 2016-07-20
US20170239216A1 (en) 2017-08-24
US20110230539A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
EA201171367A1 (ru) Винилиндазолильные соединения
UY36907A (es) Nuevas carboxamidas de acción microbiocida
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MA32562B1 (fr) Composes organiques pour la cicatrisation de lesion
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY31432A1 (es) Compuestos de diarilhidantoina
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CO6630103A2 (es) Fitocanabinoides en el tratamiento de cáncer
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
AR091837A1 (es) Compuestos para inmunoterapia dirigida
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
EA201400178A1 (ru) Лечение рака молочной железы
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
CR20110553A (es) Terapia complementaria contra el cáncer
ECSP11011245A (es) Novedosos herbicidas
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
HN2009003466A (es) Herbicidas novedosos
ECSP11011217A (es) Microbiocidas nuevos.
CO6341625A2 (es) Derivados de indol como agentes anticáncer

Legal Events

Date Code Title Description
FA Application withdrawn